ESTRO 2025 - Abstract Book

S1469

Clinical – Mixed sites & palliation

ESTRO 2025

Figure 1 – EQ-5D-5L index and visual analog scale scores during 52-week follow-up

Conclusion: Quality-of-life was stable up to one year after SABR of bone metastases in patients treated in an oligometastatic disease setting. Asymptomatic patients represent an important subpopulation and oligometastatic trials should consider this for stratification and outcome selection.

Keywords: SABR, bone, oligometastatic, quality of life

718

Digital Poster Results of a prospective feasibility study using diagnostic computed tomography for palliative radiotherapy (UMIN-CTR: UMIN000054721) Takeshi Kashiwagi, Kiyonao Nakamura, Shuji Ohtsu, Kazunori Tanaka, Tomohiro Kosuga, Kenta Fukumoto, Yuki Hanai radiation oncology, Kyoto City Hospital, Kyoto, Japan